History

Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.
DNA Repair meets diagnostics
Awards



Team

Sylvie SAUVAIGO, PhD

Stéphane ALTABA, ESCP, PhD

François-Xavier DESFORGES, PhD

Thierry MAILLET, PhD

Sarah LIBERT

Dr Giovanna MUGGIOLU

Bertrand TREILLARD

Xavier TATIN

Maria Olivia SANTIAGO

Rajat BUCHA

Sarah LIBERT

Dr Giovanna MUGGIOLU

Bertrand TREILLARD

Rajat BUCHA

Maria Olivia SANTIAGO

Rajat BUCHA
Strategic Committee

Gwenaël HAMON
Gwenaël started his career in 2009 in the Innovation Capital team of Siparex Group, before joining the Kreaxi in December 2012.
To date, he has financed nearly thirty companies, two of which are now listed, and several of which have been sold: Docea Power (Intel), Argosim (Dassault Systèmes), Itris Automation Square (Schneider Electric)...
He is a member of the Investment Committee of SATT Linksium (Grenoble).
Gwenaël is a graduate of the École Nationale Supérieure d'Arts et Métiers and of the Specialised Master in Financial Engineering of EM Lyon.

Celia HART
Celia has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and has since carried out the investments in several companies operating mainly in life sciences. She serves (or has served) on the Boards of several companies including Acusurgical, Algaia, Carthéra, Diabeloop, Fermentalg, Keranova, NH Theraguix, Uromems and Theranexus.
Prior to that Celia mainly worked for Cambridge Antibody Technology one of the most successful UK biotechnology companies (now Medimmune following its acquisition by Astra Zenena) holding different managing and product development positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in including some in collaboration with international biotechnology or pharmaceutical partners.
Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from the University of Oxford (UK) and an MBA from Grenoble École de Management (France).

Guy RIGAUD
Founder and CEO successively of the venture capital firms Sofimac and Rhône-Alpes Création (Kreaxi). More than 30 years of experience in seed and venture capital. Currently leader of a group of investors in Lyon.
Member of the Supervisory Board of Kalray (Euronext growth ALKAL) and Pherecydes Pharma (Euronext growth ALPHE).

Christian ZBYLUT
Christian Zbylut brings 35 years of experience in CEO and international top management positions in the field of logistics, transportation, and supply-chain management. In 2013, he setup an investment fund focusing on disruptive industry start-ups.
He served as regional CEO for Gefco Group before the sale of the company to the Russian Railways in December 2012. He started his career as international director for Heppner in Germany before joining Eurotunnel as freight director, and later Chep, as CEO for France. Christian Zbylut earned a Master‘s Degree in international business from the École Supérieure des Sciences Commerciales in Angers.

Sophie MANUEL

Christian DELAROCHE

Gwenaël HAMON
Gwenaël started his career in 2009 in the Innovation Capital team of Siparex Group, before joining the Kreaxi in December 2012.
To date, he has financed nearly thirty companies, two of which are now listed, and several of which have been sold: Docea Power (Intel), Argosim (Dassault Systèmes), Itris Automation Square (Schneider Electric)...
He is a member of the Investment Committee of SATT Linksium (Grenoble).
Gwenaël is a graduate of the École Nationale Supérieure d'Arts et Métiers and of the Specialised Master in Financial Engineering of EM Lyon.

Celia HART
Celia has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and has since carried out the investments in several companies operating mainly in life sciences. She serves (or has served) on the Boards of several companies including Acusurgical, Algaia, Carthéra, Diabeloop, Fermentalg, Keranova, NH Theraguix, Uromems and Theranexus.
Prior to that Celia mainly worked for Cambridge Antibody Technology one of the most successful UK biotechnology companies (now Medimmune following its acquisition by Astra Zenena) holding different managing and product development positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in including some in collaboration with international biotechnology or pharmaceutical partners.
Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from the University of Oxford (UK) and an MBA from Grenoble École de Management (France).

Guy RIGAUD
Founder and CEO successively of the venture capital firms Sofimac and Rhône-Alpes Création (Kreaxi). More than 30 years of experience in seed and venture capital. Currently leader of a group of investors in Lyon.
Member of the Supervisory Board of Kalray (Euronext growth ALKAL) and Pherecydes Pharma (Euronext growth ALPHE).

Christian DELAROCHE

Sophie MANUEL

Christian DELAROCHE
Partners










Localization
LXRepair SAS
BIOPOLIS
5, avenue du Grand Sablon
38700 La Tronche
FRANCE